Amgen Plans At-Risk Launch of EYLEA® Biosimilar Pavblu™ After Federal Circuit Lifts Temporary Injunction

Start
On October 22, 2024, the Federal Circuit (CAFC Case No. 24-2351) denied Regeneron’s request for an injunction pending appeal for Amgen’s EYLEA® (aflibercept) biosimilar Pavblu™ (aflibercept-ayyh), concluding that “Regeneron has not established that an injunction pending appeal is warranted.”…
By: Venable LLP
Previous Story

The FTC and State Case Against Amazon Highlights Risks and Impacts from Using Pricing Algorithms

Next Story

Sophos Firewall hardening best practices